Ustekinumab is superior to placebo in achieving induction response and maintaining remission in severely to moderately active Crohn disease.
↧
Channel:
Latest Crohn's Disease News on BioPortfolio
X
Are you the publisher?
Claim or
contact us
about this channel.
X
0
Channel Details:
- Title: Latest Crohn's Disease News on BioPortfolio
- Channel Number: 68069463
- Language: English
- Registered On: August 12, 2016, 11:58 am
- Number of Articles: 2985
- Latest Snapshot: April 6, 2020, 2:15 pm
- RSS URL: http://www.bioportfolio.com/news/catfeed/crohns
- Publisher: https://www.bioportfolio.com/news
- Description:
- Catalog: //bioportfolio262.rssing.com/catalog.php?indx=68069463
© 2024 //www.rssing.com